Accessibility Menu
Santhera Pharmaceuticals Ag logo

Santhera Pharmaceuticals Ag(OTC) SPHDF

Market Cap$344.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-91%
5 Year-25%
1 Year+58%
1 Month+0%
$23.25
+1.75%
+0.40Today
Santhera Pharmaceuticals Ag last closing stock price
MetricPriceDate
Last closeUSD 23.252026-06-23
Santhera Pharmaceuticals Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 23.252026-04-28
1 month+0%USD 23.252026-04-28
3 month+19.48%USD 19.462026-03-25
Year to date+74.16%USD 13.352025-12-16
1 year+57.63%USD 14.752025-05-28
3 year+241.91%USD 6.802023-06-21
5 year-25%USD 31.002021-06-24
Since inception-91.31%USD 267.502009-05-19

Santhera Pharmaceuticals Ag Financials at a Glance

Market Cap

$344.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 116.33M

Net Income (TTM)

-CHF 91.21M

EPS (TTM)

-$4.50

P/E Ratio

-5.17

Dividend

$0.00

Beta (Volatility)

-0.05 (Low)

Price

$23.25

Volume

40

Open

$23.25

Previous Close

$23.25

Daily Range

$23.25 - $23.25

52-Week Range

$12.28 - $23.25

Estimated Earnings Date

Sep 21, 2026

SPHDF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Santhera Pharmaceuticals Ag

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on developing and selling medicines for rare neuromuscular and pulmonary diseases. The company operates in Europe, North America, and Asia, addressing high unmet medical needs with innovative therapies.

Products and Services
  • Vamorolone for Duchenne muscular dystrophy treatment
  • Lonodelestat for cystic fibrosis and neutrophilic pulmonary diseases
  • Pipeline of additional therapies targeting rare diseases
Growth Outlook
  • Strong pipeline with potential for significant market impact
  • Expansion into new markets expected to drive revenue growth
  • Focus on rare diseases aligns with increasing healthcare demand
Financial Highlights
  • Recent quarterly revenue of 53.2 million CHF, showing growth
  • Trailing twelve months (TTM) revenue of 99.4 million CHF
  • Operating income margin improved to 71.2% in Q4 2023
Santhera Pharmaceuticals Holding AG is positioned in a niche market with a focus on rare diseases, which often have limited treatment options. The company's lead product, Vamorolone, is in advanced stages of development, targeting a significant patient population with Duchenne muscular dystrophy. The recent financial performance indicates a positive trajectory, with substantial revenue growth in the latest quarter and a strong TTM revenue figure. The operating income margin improvement reflects effective cost management and operational efficiency. As the company continues to expand its product offerings and market presence, it may attract interest from investors looking for opportunities in the healthcare sector.
AI Generated • Jul 9, 2026

Industry

Biotechnology

Sector

Health Care

Employees

93.6

CEO

Dario Eklund

Website

www.santhera.com

Headquarters

Pratteln, BL 4133, CH

SPHDF Financials

Key Financial Metrics (TTM)

Gross Margin

18.74%

Operating Margin

-48.99%

Net Income Margin

-63.79%

Return on Equity

684.83%

Return on Capital

-44.00%

Return on Assets

-33.25%

Earnings Yield

-19.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$344.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.83M

Volume

40

Avg. Volume

0.635

Financials (TTM)

Gross Profit

CHF 38.07M

Operating Income

-CHF 71.14M

EBITDA

-CHF 48.49M

Operating Cash Flow

-CHF 70.30M

Capital Expenditure

-CHF 274.02K

Free Cash Flow

-CHF 70.57M

Cash & ST Invst.

CHF 22.45M

Total Debt

CHF 97.81M

Santhera Pharmaceuticals Ag Performance Analysis

Santhera Pharmaceuticals Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 7,824,597N/A
20232023-12-31CHF 115,076,8361370.7%
20242024-12-31CHF 44,417,441-61.4%
20252025-12-31CHF 92,939,529109.2%
Santhera Pharmaceuticals Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-85.8%
Q42024-12-3177.2%
Q22025-06-30-4.0%
Q42025-12-31121.5%
Santhera Pharmaceuticals Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -12.21-31.3%
20232023-12-31CHF 5.58N/A
20242024-12-31CHF -4.19N/A
20252025-12-31CHF -4.568.8%
Santhera Pharmaceuticals Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-119.3%
Q42024-12-31-73.3%
Q22025-06-30-29.9%
Q42025-12-3174.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CHF 53.20M

-46.5%

Gross Profit

CHF 22.93M

-76.6%

Gross Margin

43.11%

N/A

Market Cap

$344.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.42M

N/A

Employees

78

N/A

Net Income

-CHF 10.41M

-113.3%

EBITDA

CHF 480.23K

-99.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CHF 22.45M

-26.1%

Total Debt

CHF 97.81M

+353.9%

Accounts Receivable

CHF 26.05M

+5820.6%

Inventory

CHF 24.88M

+1273.8%

Long Term Debt

CHF 74.07M

+4037.0%

Short Term Debt

CHF 14.85M

-31.0%

Return on Assets

-33.25%

N/A

Return on Invested Capital

-44.02%

N/A

Free Cash Flow

-CHF 14.22M

-122.7%

Operating Cash Flow

-CHF 14.17M

-122.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLNCFSilence Therapeutics plc
$1.50+0.00%
IPHYFInnate Pharma S.A.
$1.65+0.00%
MLLCFMolecular Partners AG
$3.80+0.00%
NDTPNDT Pharmaceuticals Inc.
$0.55-0.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$108.96-0.13%
NVDANvidia
$221.65+0.05%
ONDSOndas
$8.88+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.04%

Questions About SPHDF

What is the current price of Santhera Pharmaceuticals Ag?

Santhera Pharmaceuticals Ag is trading at $23.25 per share.

What is the 52-week range for Santhera Pharmaceuticals Ag?

Over the past 52 weeks, Santhera Pharmaceuticals Ag has traded between $12.28 and $23.25.

How much debt does Santhera Pharmaceuticals Ag have?

As of the most recent reporting period, Santhera Pharmaceuticals Ag reported total debt of CHF 123.40M.

How much cash does Santhera Pharmaceuticals Ag have on hand?

Santhera Pharmaceuticals Ag reported CHF 28.32M in cash and cash equivalents in its most recent financial results.

What is Santhera Pharmaceuticals Ag’s dividend yield?

Santhera Pharmaceuticals Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services